|Bid||7.81 x 1300|
|Ask||7.84 x 2200|
|Day's Range||7.76 - 8.04|
|52 Week Range||5.81 - 19.00|
|Beta (5Y Monthly)||0.62|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 08, 2021 - Nov 12, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||13.22|
Is INO stock a buy after Brazil, the Philippines and Mexico gave it the go-ahead to run Covid vaccine testing? Is Inovio stock a buy now?
INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that it has received authorization from COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios), the national health regulatory agency of Mexico, to conduct a clinical trial in that country as part of the Phase 3 segment of INOVIO's global Phase 2/3 trial, INNOVATE (I
Company's COVID vaccine candidate has lower likely returns than other therapies with longer timelines, BofA said.